Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka

Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15

HOS-136591 · Präparat HOS-097888

14  Tenofovir: AUC: ↔ Cmax: ↑ 55% (↑ 43 to ↑ 68) Cmin: ↑ 39% (↑ 31 to ↑ 48) Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations of (400 mg/100 mg q.d.) + AUC: ↓ 28% (↓ 34 to ↓ 20) tenofovir resulting from co Darunavir/Ritonavir Cmax: ↓ 38% (↓ 46 to ↓ 29) administration of tenofovir disoproxil, (800 mg q.d./100 mg q.d.) + sofosbuvir/velpatasvir and Emtricitabine/Tenofovir disoproxil GS-3310072: darunavir/ritonavir may increase (200 mg/245 mg q.d.) AUC: ↔ adverse reactions related to tenofovir Cmax: ↔ disoproxil, including renal disorders. Cmin: ↔ The safety of tenofovir disoproxil when used with sofosbuvir/velpatasvir and a Velpatasvir: pharmacokinetic enhancer (e.g. AUC: ↔ ritonavir or cobicistat) has not been Cmax: ↓ 24% (↓ 35 to ↓ 11) established. Cmin: ↔ The combination should be used with Darunavir: caution with frequent renal monitoring AUC: ↔ (see section 4.4). Cmax: ↔ Cmin: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521)